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CLINICAL AND POPULATION STUDIES
Serum Calcification Propensity and the Risk of 
Cardiovascular and All-Cause Mortality in the 
General Population
The PREVEND Study
Coby Eelderink, Charlotte A. te Velde-Keyzer, Anne-Roos S. Frenay, Emma A. Vermeulen, Matthias Bachtler,  
Parisa Aghagolzadeh, Peter R. van Dijk, Ronald T. Gansevoort, Marc G. Vervloet, Jan-Luuk Hillebrands, Stephan J.L. Bakker,  
Harry van Goor,* Andreas Pasch,* Martin H. de Borst ,* on behalf of the NIGRAM2+ consortium
OBJECTIVE: Vascular calcification contributes to the cause of cardiovascular disease. The calciprotein particle maturation time 
(T50) in serum, a measure of calcification propensity, has been linked with adverse outcomes in patients with chronic kidney 
disease, but its role in the general population is unclear. We investigated whether serum T50 is associated with cardiovascular 
mortality in a large general population-based cohort.
APPROACH AND RESULTS: The relationship between serum T50 and cardiovascular mortality was studied in 6231 participants 
of the PREVEND (Prevention of Renal and Vascular End-Stage Disease) cohort. All-cause mortality was the secondary 
outcome. Mean (±SD) age was 53±12 years, 50% were male, and mean serum T50 was 329±58 minutes. A shorter serum 
T50 is indicative of a higher calcification propensity. Serum T50 was inversely associated with circulating phosphate, age, 
estimated glomerular filtration rate, and alcohol consumption, whereas plasma magnesium was positively associated with 
serum T50 (P<0.001, total multivariable model R
2=0.281). During median (interquartile range) follow-up for 8.3 (7.8–8.9) 
years, 364 patients died (5.8%), of whom 95 (26.1%) died from a cardiovascular cause. In multivariable Cox proportional 
hazard models, each 60 minutes decrease in serum T50 was independently associated with a higher risk of cardiovascular 
mortality (fully adjusted hazard ratio [95% CI], 1.22 [1.04–1.36], P=0.021). This association was modified by diabetes 
mellitus; stratified analysis indicated a more pronounced association in individuals with diabetes mellitus.
CONCLUSIONS: Serum T50 is independently associated with an increased risk of cardiovascular mortality in the general population 
and thus may be an early and potentially modifiable risk marker for cardiovascular mortality.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: association ◼ calcification propensity (T50) ◼ calciprotein particles ◼ cardiovascular diseases ◼ diabetes mellitus ◼ mortality ◼ population
Coronary calcification is a risk factor for cardiovas-cular morbidity and mortality in the general popula-tion, independent of traditional cardiovascular risk 
factors.1–4 Similarly, calcification of other vascular beds, 
including the thoracic5,6 and abdominal aorta,7 and the 
breast artery,8 has been independently associated with 
cardiovascular morbidity and mortality. The susceptibil-
ity to vascular calcification and the strength of the rela-
tionship with outcomes may vary among vascular beds. 
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(co-)occur, including intimal atherosclerotic calcification, 
arterial media calcification (which is common in patients 
with type 2 diabetes mellitus or chronic kidney disease 
[CKD]), and valvular calcification.9 These calcification 
types seem to be driven by both local processes and sys-
temic factors like inflammation and metabolic derange-
ments,9 which may concertedly result in a more general 
calcification propensity, predisposing to adverse clinical 
outcomes.10 Currently used techniques to detect mani-
fest vascular calcification, mostly based upon computed 
tomography, are incapable to quantify the intrinsic pro-
pensity to develop future calcifications.
An in vitro blood test has been developed that quanti-
fies calcification propensity in serum.11 Under physiologi-
cal circumstances, the precipitation of supersaturated 
calcium and phosphate in serum is prevented by the 
formation of primary calciprotein particles (CPP), which 
may subsequently transform to more harmful, secondary 
CPP.12,13 The transformation time from primary to second-
ary CPP, known as the serum T50, reflects the endogenous 
defense capacity against calcium-phosphate precipitation. 
In patients prone to vascular calcification, such as patients 
with CKD, circulating CPP has been associated with aortic 
stiffness and vascular calcification.14,15 Moreover, a shorter 
serum T50 (ie, accelerated precipitation time) has been 
associated with all-cause mortality in patients with CKD16 
and hemodialysis,17 and with all-cause and cardiovascular 
mortality in renal transplant recipients,18,19 independent of 
established cardiovascular risk factors. However, recently, 
it was shown in patients with CKD (stage 2–4), that the 
association of T50 with cardiovascular and all-cause mor-
tality was not independent of renal function.20
To extend these findings, we broadened the research 
field of calcification propensity to the general popula-
tion. We investigated the relationship between serum 
T50, established cardiovascular risk factors and other rel-
evant clinical and biochemical parameters, and whether 
serum T50 is independently associated with the risk of 
cardiovascular mortality and all-cause mortality in a large, 
general population-based cohort.
METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request. The 
article is written in compliance with the STROBE guidelines for 
observational studies.21
Study Population
The PREVEND study (Prevention of Renal and Vascular End-
Stage Disease) is a prospective cohort that was designed to 
study the association of microalbuminuria with renal and car-
diovascular disease in the general population. Details of the 
PREVEND study have been published previously.22,23 In brief, 
between 1997 and 1998, inhabitants of the city of Groningen, 
The Netherlands, aged 28 to 75 years (n=85 421), received a 
questionnaire and a vial to collect an early morning urinary sam-
ple. Of these subjects, 40 856 responded (47.8%) and sent 
back their vial to a central laboratory where urinary albumin and 
creatinine concentrations were measured. Two subgroups were 
derived from this population: 9966 individuals with a urinary 
albumin concentration ≥10 mg/L and 30 890 subjects with uri-
nary albumin concentration <10 mg/L. After the exclusion of 
subjects with insulin-dependent diabetes mellitus and pregnant 
women, 7768 subjects with a urinary albumin concentration 
≥10 mg/L were invited to participate (n=6000 enrolled) and a 
randomly selected control group with a urinary albumin concen-
tration <10 mg/L was invited (n=2592 enrolled). These 8592 
individuals form the PREVEND cohort and were further inves-
tigated in an outpatient clinic. The PREVEND study has been 
approved by the medical ethics committee of the University 
Medical Center Groningen and was performed in accordance 
with the declaration of Helsinki. All participants provided written 
informed consent.
For the measurement of serum T50 in this cohort, serum 
samples were available from the second examination round, 
which took place between April 2001 and November 2003. 
This resulted in data from 6231 participants for the current 
analysis.
Measurements and Definitions
The procedures at each examination in the PREVEND study 
have been described in detail previously.24,25 In brief, each 
examination included 2 visits to an outpatient clinic separated 
by 3 weeks. For the baseline survey, participants completed 
Nonstandard Abbreviations and Acronyms
BMI body mass index
CKD chronic kidney disease
CPP calciprotein particles
eGFR estimated glomerular filtration rate
HR hazard ratio
hsCRP high-sensitivity C-reactive protein
ICD-9  International Classification of Diseases, 
Ninth Revision
PREVEND  Prevention of Renal and Vascular End-
Stage Disease
serum T50 measure of calcification propensity
Highlights
• The transformation time from primary to second-
ary calciprotein particles, known as the serum T50, 
reflects the endogenous defense capacity against 
calcium-phosphate precipitation.
• Serum T50 is independently associated with an 
increased risk of cardiovascular mortality in the gen-
eral population.
• Serum T50 may have a higher predictive value in 
subgroups that are at a higher risk of developing 
medial calcifications or cardiovascular disease, such 
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a questionnaire obtaining information on demographics, race, 
cardiovascular and renal disease history, alcohol consumption, 
smoking status, and medication use. Self-reported medication 
use was complemented by information garnered from commu-
nity pharmacies. Data on specific medications were based on 
pharmacy information only.
Furthermore, body weight, height, and waist and hip cir-
cumference were measured. During both visits of the second 
examination round, blood pressure was measured in a supine 
position on the right arm, every minute for 10 and 8 minutes, 
respectively, by an automatic Dinamap XL Model 9300 series 
device (Johnson-Johnson Medical, Tampa, FL). The mean 
of the last 2 recordings from each of the 2 visits was used. 
Hypertension was defined as systolic blood pressure >140 
mm Hg, diastolic blood pressure >90 mm Hg, or use of antihy-
pertensive medication.
Fasting blood samples were taken and stored at −80°C until 
further processing. Circulating albumin, hemoglobin, calcium, 
phosphate, magnesium, parathyroid hormone, creatinine, blood 
lipids, glucose, and hsCRP (high-sensitivity C-reactive protein) 
were determined using standard methods or as previously 
described.26–28 Circulating calcium concentrations were cor-
rected for albumin concentrations as follows: corrected calcium 
= calcium (mmol/L)+0.02×(40-albumin [g/L]). The estimated 
glomerular filtration rate (eGFR) was calculated by using the 
creatinine-cystatin C-based CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration) equation, taking into account age, 
sex, and race.29 Diabetes mellitus was defined according to 
the guidelines of the American Diabetes Association as a fast-
ing plasma glucose ≥7.0 mmol/L (126 mg/dL) or the use of 
blood glucose-lowering medication. Hypercholesterolemia was 
defined as total serum cholesterol >6.2 mmol/L (240 mg/dL) 
or the use of lipid-lowering medication. Albuminuria and urinary 
sodium excretion were measured in 24-hour urine samples, 
obtained after thorough oral and written instruction.30
Serum T50 measurements were performed as described 
previously.18 In brief, samples were measured in a blinded man-
ner in triplicates in 384-well plates at 37°C for 600 minutes 
in a Nephelostar nephelometer (BMG Labtech, Ortenberg, 
Germany). Stock calcium and phosphate solutions were used, 
with pH adjusted to 7.40 at 37°C in both solutions. For T50 mea-
surements, 35 μL of calcium solution was mixed with 40 μL 
serum, and then 25 μL of the phosphate solution was added. 
Data analyses of nonlinear regression curves were performed 
using Microsoft Excel software to determine the half-maximal 
precipitation time (T50). The analytical coefficients of variation 
of standards precipitating at 120, 260, and 390 minutes were 
7.8%, 5.1%, and 5.9%, respectively.
Clinical End Points
The primary outcome of our longitudinal analyses was cardio-
vascular mortality, whereas the secondary outcome of our study 
was all-cause mortality. We studied incident fatal or nonfatal 
cardiovascular events as an exploratory outcome. Information 
on hospitalization for cardiovascular morbidity was obtained 
from PRISMANT, the Dutch national registry of hospital dis-
charge diagnoses. Clinical event data were coded according 
to the International Classification of Diseases, Ninth Revision 
(ICD-9) and the classification of health interventions. Incident 
coronary artery disease was defined as fatal or nonfatal acute 
myocardial infarction (ICD-9 code 410), acute and subacute 
ischemic heart disease (code 411), coronary artery bypass 
grafting (code 414), or percutaneous transluminal coronary 
angioplasty. Stroke events were defined as subarachnoid 
hemorrhage (code 430), intracerebral hemorrhage (code 
431), other intracranial hemorrhage (code 432), or occlusion 
or stenosis of the precerebral (code 433) or cerebral (code 
434) arteries. Peripheral artery disease was defined as vas-
cular interventions such as percutaneous transluminal angio-
plasty or bypass grafting of aorta and peripheral vessels. From 
the time of recruitment, the vital status of the participants was 
checked through the municipal register. The cause of death 
was obtained by linking the number of the death certificate to 
the primary cause of death as coded by a physician from the 
Central Bureau of Statistics in The Netherlands. The survival 
time was defined as the period from the date of serum collec-
tion of the participant until the date of first cardiovascular event, 
date of death, or end of follow-up.
Statistical Analyses
Continuous variables with a normal distribution are expressed 
as mean with SD. Variables with a skewed distribution are given 
as median (interquartile range) and were normalized using nat-
ural logarithmic transformation before use in parametric tests. 
P trend over the quintiles of serum T50 (based on the median 
T50 values for each quintile) was calculated by linear regression 
analysis for continuous variables or χ2 linear-by-linear associa-
tion for categorical data.
For the screening of the PREVEND study, subjects with 
an elevated albuminuria were overselected to acquire suffi-
cient subjects with microalbuminuria. To overcome the effect of 
oversampling of subjects with elevated albuminuria, all models 
took the sampling design into account by specifying stratum-
specific baseline hazard functions. Owing to this statistical 
weighing method, our conclusions may also be generalized to 
subjects with normal levels of albuminuria.
Our study cohort was used to examine the association of 
T50 with traditional cardiovascular risk factors, renal function, 
and other relevant clinical and biochemical parameters. Main 
determinants of serum T50 were evaluated using a backwards 
linear regression model in which variables were included that 
were significantly associated with T50 upon univariable linear 
regression. In longitudinal primary analyses, the association of 
T50 with cardiovascular mortality was investigated using Cox 
proportional hazard models. Model 1 is a basic model adjusted 
for age and sex. In model 2, we further adjusted for cardio-
vascular risk factors (smoking, systolic blood pressure, use of 
antihypertensive medication, plasma glucose, use of glucose-
lowering medication, total cholesterol, use of lipid-lowering 
medication, history of cardiovascular events, body mass index 
[BMI], and hsCRP). In model 3, we additionally adjusted for 
alcohol consumption and eGFR, representing the determinants 
of serum T50 (derived from the backwards linear regression 
model) without a known direct (in vitro) accelerating (eg, phos-
phate) or delaying (eg, magnesium) effect on T50. Using the 
same Cox regression models, we conducted secondary analy-
sis to investigate the association of T50 with all-cause mortality.
To investigate the value of serum T50 over plasma phosphate 
as a risk marker for (cardiovascular) mortality, the same models 
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analyses, we studied the association of decreasing serum T50 
with incident fatal or nonfatal cardiovascular events using the Cox 
regression models described above (except for adjustment for 
history of cardiovascular events). For these analyses, subjects with 
a history of the studied cardiovascular event outcome (eg, inci-
dent cardiovascular events, coronary artery disease, stroke, heart 
failure, and peripheral artery disease) were excluded beforehand.
To retain the number of events in adjusted Cox models, 
missing data in covariables (for details see Table I in the Data 
Supplement) were handled by multiple (n=5) imputations31,32 
using the linear regression method in SPSS.
The ability of the models to distinguish those with an event 
from those without, was evaluated with Harrell C index. Harrell 
C index is analogous to the area under the receiver operating 
characteristic curve, for which larger values indicate better dis-
crimination. We examined potential nonlinear relationships by 
fitting restricted cubic spline transformations with 3 knots on a 
Cox model adjusted for age and sex and comparing them with 
linear splines. We explored possible effect modification by age, 
sex, BMI, eGFR, diabetes mellitus, plasma magnesium, and 
plasma phosphate for the association between T50 and cardio-
vascular and all-cause mortality by using multiplicative interac-
tion terms (where applicable with continuous data), followed 
by stratified Cox regression analysis based on median values.
Statistical analyses were performed using SPSS version 
23.0 for Windows (IBM Corporation, Chicago, IL) and STATA 
Statistical Software: Release 14 (StataCorp, College Station, 
TX). Figures were made using GraphPad Prism 7.02 (GraphPad 




The mean age of participants was 53.5±12.0 years, 49.9% 
were male, and mean serum T50 was 329±58 minutes. 
The prevalence of diabetes mellitus was 2.7%, 33.2% 
had hypertension, 18.5% were obese (BMI ≥30 kg/m2), 
30.3% had hypercholesterolemia, and 28.2% were cur-
rent smokers. Mean eGFR was 92.2±17.1 mL/min per 
1.73 m2, and 4.3% of the participants had an eGFR <60 
mL/min per 1.73 m2. Baseline characteristics of the 6231 
participants, according to quintiles of T50, are presented in 
Table 1. Subjects with a shorter T50 (ie, higher calcifica-
tion propensity) were more likely to be female, to consume 
more alcohol and to smoke (all P<0.001). The mean dif-
ference in serum T50 between men and women was ≈20 
minutes (339±58 and 320±56 minutes, respectively).
During follow-up for a median of 8.3 (7.8–8.9) years, 
364 patients died (5.8%), of whom 95 (26.1%) from a 
cardiovascular cause.
Determinants of Serum T50
Multivariable linear regression analysis (Table 2) showed 
that plasma phosphate, age, and plasma magnesium 
were the strongest determinants of serum T50. Higher 
phosphate concentrations and older age were associated 
with a shorter T50, whereas higher magnesium concen-
trations were associated with a longer T50 (ie, lower calci-
fication propensity). In addition, eGFR and alcohol intake 
were inversely associated with T50 (ie, increased calci-
fication propensity with higher eGFR and more alcohol 
consumption). Other determinants of serum T50 in this 
population were albumin, smoking, calcium, cholesterol, 
glucose, parathyroid hormone, and systolic blood pres-
sure (see Table 2 for directions of effects). The total mul-
tivariable model had an overall R2 of 0.281.
T50 and Cardiovascular Mortality
In a basic Cox regression model adjusted for age and sex, 
a shorter serum T50 was associated with an increased risk 
of cardiovascular mortality (model 1, hazard ratio [HR; 
95% CI], 1.24 [1.07–1.38], P=0.007; Table 3). This rela-
tionship is depicted as a linear spline curve in Figure 1A. 
Serum T50 was associated with cardiovascular mortality 
independent of other cardiovascular risk factors (model 
2), and independent of other possible confounders 
(model 3, fully adjusted HR, 1.22 [1.04–1.36], P=0.021).
For BMI, plasma magnesium, and diabetes mellitus 
significant effect modification was found in the associa-
tion between T50 and cardiovascular mortality (Pinteraction 
<0.1). Stratified analyses indicated a more pronounced 
relationship between serum T50 and the risk of cardio-
vascular mortality in subjects with diabetes mellitus 
(HR, 1.54 [1.15–1.76], P=0.013). In addition, the asso-
ciations were mainly present for subjects with a higher 
BMI (>26.1 kg/m2) or lower plasma magnesium (<0.82 
mmol/L; Figure 2).
T50 and All-Cause Mortality
Multivariable Cox regression analysis also revealed that 
serum T50 was associated with all-cause mortality in a 
basic model adjusted for age and sex (model 1, HR, 1.12 
[1.03–1.21], P=0.014), depicted as a spline curve in Fig-
ure 1B. The association did not remain significant after 
adjustment for several cardiovascular risk factors and 
other potential confounders (fully adjusted HR [model 3], 
1.10 [0.99–1.19], P=0.064).
Significant effect modification by diabetes mellitus 
was observed in the association between T50 and all-
cause mortality (Pinteraction <0.1). Stratified analyses indi-
cated that the increased risk for all-cause mortality per 
60 minutes decrease in T50 was most pronounced in par-
ticipants with diabetes mellitus (HR, 1.43 [1.14–1.62], 
P=0.007; Figure I in the Data Supplement).
Exploratory Analyses—Phosphate and 
(Cardiovascular) Mortality
The value of serum T50 over plasma phosphate as a risk 
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Table 1. Baseline Characteristics of the Cohort Per Quintiles of Serum T50*
T50 (min)
Quintiles of Serum T50
P for 
Trend
Quintile 1  
N=1245; <284
Quintile 2  
N=1243; 284–315
Quintile 3  
N=1244; 315–344
Quintile 4  
N=1249; 344–378
Quintile 5  
N=1250; >378
Demographics
 Male sex, n (%) 476 (38.2) 574 (46.2) 601 (48.3) 667 (53.4) 793 (63.4) <0.001
 Age, y 54.0±11.7 53.5±11.7 54.2±12.0 52.7±12.0 53.1±12.7 0.024
 Current smoking 459 (37.3) 360 (29.1) 322 (26.2) 314 (25.5) 283 (23.0) <0.001
 Alcohol consumption <0.001
  No, almost never 265 (21.5) 302 (24.5) 308 (25.0) 332 (26.8) 334 (27.0)  
  1–4 drinks/mo 191 (15.5) 198 (16.0) 223 (18.1) 214 (17.3) 239 (19.3)  
  2–7 drinks/wk 351 (28.4) 391 (31.7) 399 (32.3) 391 (31.6) 418 (33.8)  
  1–3 drinks/d 347 (28.1) 295 (23.9) 255 (20.7) 249 (20.1) 214 (17.3)  
  >3 drinks/d 80 (6.5) 49 (4.0) 49 (4.0) 51 (4.1) 33 (2.7)  
 History of CV events 75 (6.0) 86 (6.9) 97 (7.8) 74 (5.9) 78 (6.2) 0.861
Body composition
 BMI, kg/m2 26.0±4.2 26.5±4.4 27.1±4.4 26.8±4.2 26.8±4.2 <0.001
 Waist/hip, ratio 0.88±0.09 0.90±0.09 0.90±0.08 0.90±0.08 0.92±0.08 <0.001
Blood pressure
 Systolic BP, mm Hg 123.2±18.9 125.2±18.8 126.2±18.3 126.9±18.6 129.1±18.9 <0.001
 Diastolic BP, mm Hg 72.4±9.3 73.1±8.9 73.2±8.9 73.7±9.2 74.5±9.3 <0.001
Renal function
 eGFR, mL/min per 1.73 m2 93.3±17.3 92.8±16.8 91.2±17.1 92.7±16.7 90.9±17.5 0.002
 Albuminuria, mg/24 h 8.7 (6.0–15.4) 9.0 (6.2–15.6) 8.4 (6.0–15.6) 8.7 (6.1–16.5) 9.0 (6.2–16.5) 0.186
 ACR, mg/mmol 0.79 (0.54–1.36) 0.77 (0.54–1.37) 0.72 (0.50–1.37) 0.71 (0.50–1.36) 0.72 (0.48–1.37) 0.064
Other urinary parameter
 Sodium excretion, mmol/24 h 139±52 144±54 147±54 146±56 148±57 <0.001
Glucose
 Type 2 diabetes mellitus, n (%) 29 (2.3) 34 (2.7) 39 (3.1) 31 (2.5) 34 (2.7) 0.681
 Glucose, mmol/L 4.7 (4.4–5.2) 4.7 (4.4–5.3) 4.8 (4.4–5.3) 4.8 (4.4–5.3) 4.8 (4.5–5.3) <0.001
Lipids
 Total cholesterol, mmol/L 5.41±1.05 5.40±1.06 5.44±1.01 5.44±1.06 5.49±1.06 0.024
 HDL cholesterol, mmol/L 1.32±0.34 1.27±0.30 1.24±0.31 1.23±0.30 1.23±0.31 <0.001
 Triglycerides, mmol/L 0.99 (0.73–1.40) 1.07 (0.77–1.53) 1.13 (0.83–1.65) 1.15 (0.83–1.65) 1.24 (0.88–1.76) <0.001
Other plasma parameters
 Hemoglobin, mmol/L 8.3±0.8 8.4±0.7 8.5±0.7 8.6±0.7 8.7±0.8 <0.001
 Calcium (corrected), mmol/L 2.23±0.08 2.23±0.07 2.23±0.07 2.23±0.08 2.24±0.07 0.021
 Phosphate, mmol/L 1.11±0.15 1.04±0.15 0.99±0.15 0.95±0.14 0.90±0.14 <0.001
 Magnesium, mmol/L 0.81±0.06 0.82±0.05 0.82±0.05 0.83±0.05 0.84±0.05 <0.001
 PTH, pmol/L 5.01±1.85 5.03±1.45 5.10±1.73 5.17±1.62 5.30±1.71 <0.001
 Albumin, g/L 43.4±2.5 43.5±2.6 43.5±2.5 43.9±2.7 44.3±2.9 <0.001
 hsCRP, mg/L 1.18 (0.56–2.73) 1.37 (0.61–3.07) 1.35 (0.63–3.19) 1.40 (0.63–3.09) 1.40 (0.65–2.96) 0.069
Medication use
  Aspirin 28 (2.3) 31 (2.6) 37 (3.0) 36 (2.9) 33 (2.7) 0.415
  Vitamin K antagonist 35 (2.9) 22 (1.8) 24 (2.0) 16 (1.3) 19 (1.6) 0.011
 Antihypertensive drug use 238 (19.1) 260 (20.9) 276 (22.2) 259 (20.7) 279 (22.3) 0.112
  Diuretics 63 (5.3) 70 (5.9) 71 (6.0) 71 (6.0) 97 (8.2) 0.006
  β-blocker 112 (9.4) 126 (10.6) 131 (11.1) 116 (9.7) 124 (10.5) 0.555
  ACE inhibitors/ARBs 108 (8.9) 98 (8.1) 114 (9.4) 100 (8.2) 106 (8.8) 0.753
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with the same Cox regression models. Circulating phos-
phate was not associated with cardiovascular mortal-
ity nor with all-cause mortality (Table II in the Data 
Supplement).
Exploratory Analyses—T50 and Cardiovascular 
Events
Cox regression models exploring the possible associa-
tion of serum T50 with incident cardiovascular events, cor-
onary artery disease, stroke, heart failure, or peripheral 
artery disease are shown in Table III in the Data Supple-
ment. No significant associations were observed with the 
incidence of specific cardiovascular events.
DISCUSSION
In this prospective cohort study, we addressed the asso-
ciation between serum T50 and the risk of cardiovascular 
mortality and all-cause mortality in the general population. 
The primary finding is that a shorter serum T50, reflect-
ing higher calcification propensity, is associated with a 
higher risk of cardiovascular mortality. This association 
was independent of established cardiovascular risk fac-
tors, and more pronounced in certain subgroups, such 
as participants with diabetes mellitus, overweight or low 
plasma magnesium. There was no association with all-
cause mortality after multivariable adjustment.
The determination of calcification propensity, reflected 
by the serum T50, is an increasingly used risk prediction 
tool in medicine,11 especially in the field of nephrology. 
When serum of individual subjects is challenged with 
supersaturated calcium and phosphate solutions, spon-
taneous formation of (additional) primary CPP, which 
contain amorphous calcium phosphate, is triggered. 
These nano-sized particles then undergo, at time point 
T50, which is specific for individual serum samples, spon-
taneous conversion to more harmful crystalline cal-
cium phosphate-containing secondary CPP.12 Thereby, 
calcification propensity, as measured by the T50 test, 
reflects the functional integrity of a relevant protective 





Plasma phosphate −0.456 −0.477 −0.429 <0.001
Age −0.171 −0.205 −0.137 <0.001
Plasma magnesium 0.157 0.133 0.181 <0.001
eGFR (creat-cysC) −0.114 −0.146 −0.083 <0.001
Alcohol intake −0.113 −0.137 −0.090 <0.001
Plasma albumin 0.105 0.079 0.130 <0.001
Current smoking −0.068 −0.092 −0.045 <0.001
Total cholesterol 0.056 0.033 0.080 <0.001
Plasma calcium (corrected) 0.051 0.027 0.076 <0.001
Plasma PTH −0.040 −0.064 −0.017 0.001
Plasma glucose 0.037 0.014 0.064 0.002
Systolic blood pressure 0.030 0.003 0.058 0.027
Plasma hemoglobin 0.025 −0.002 0.051 0.069
BMI indicates body mass index; eGFR, estimated glomerular filtration rate; and 
PTH, parathyroid hormone.
*Multivariable linear regression model obtained using backward selection of 
covariables (using Z scores) associated with serum T50 at baseline. Explained 
variance R2=0.281. Variables not independently associated with serum T50 
included hemoglobin, body mass index, urinary sodium excretion, and sex.
Table 3. Hazard Ratios of Cardiovascular Mortality and All-
Cause Mortality Per 60 Minutes Decrease in T50*
Per 60 Minutes Decrease in T50  
HR (95% CI) P Value Harrell C
Cardiovascular mortality (95 events)
 Model 1 1.24 (1.07–1.38) 0.007 0.873
 Model 2 1.20 (1.02–1.35) 0.032 0.908
 Model 3 1.22 (1.04–1.36) 0.021 0.908
All-cause mortality (364 events)
 Model 1 1.12 (1.03–1.21) 0.014 0.820
 Model 2 1.09 (0.99–1.18) 0.079 0.840
 Model 3 1.10 (0.99–1.19) 0.064 0.839
Model 1: adjusted for age and sex; Model 2: model 1 + adjusted for smoking, 
systolic blood pressure, use of antihypertensive medication, plasma glucose, use 
of glucose-lowering medication, total cholesterol, use of lipid-lowering medica-
tion, history of CV events, BMI, and hsCRP (CV risk factors); and Model 3: model 
2 + adjusted for alcohol consumption and eGFR (determinants of serum T50 with-
out a known direct (in vitro) accelerating or delaying effect on T50). BMI indicates 
body mass index; CV, cardiovascular; eGFR, estimated glomerular filtration rate; 
HR, hazards ratio; and hsCRP, high-sensitivity C-reactive protein.
*Hazard ratios and 95% CI were derived from Cox proportional hazards regres-
sion models. N=6231.
  Statines 83 (7.0) 94 (7.9) 114 (9.6) 91 (7.6) 88 (7.5) 0.733
 Glucose-lowering drug use 20 (1.6) 26 (2.1) 25 (2.0) 19 (1.5) 13 (1.0) 0.151
ACE indicates angiotensin-converting enzyme; ACR, albumin creatinine ratio; ARBs, angiotensin receptor blockers; BMI, body mass index; BP, blood pressure; CV, 
cardiovascular; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; and PTH, 
parathyroid hormone.
*Values are mean±SD if normally distributed, median (IQR) if non-normally distributed, or number (%) for categorical variables. P value was calculated by linear regres-
sion analysis (after natural logarithmic transformation where applicable) for continuous variables or χ2 linear-by-linear association for categorical data.
Table 1. Continued
T50 (min)
Quintiles of Serum T50
P for 
Trend
Quintile 1 N=1245; 
<284
Quintile 2 N=1243; 
284–315
Quintile 3 N=1244; 
315–344
Quintile 4 N=1249; 
344–378
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taken into consideration. This system is thought to con-
sist of calcification promotors and inhibitors, where an 
imbalance (eg, due to disease conditions such as kidney 
failure) of this dynamic system would lead to increased 
calcifications.14,15
From the multivariable regression analysis, phosphate 
appeared as the strongest determinant of T50, showing 
an inverse association with serum T50, as expected due to 
its prominent role in CPP formation. In a study in people 
with moderate CKD, higher serum phosphate concentra-
tions, although still within the normal range, were previ-
ously associated with a greater prevalence of vascular 
calcification.33 Magnesium was also a strong determinant 
of serum T50, with higher plasma magnesium concentra-
tions being associated with a longer T50 (eg, decreased 
calcification propensity), which is in line with results from 
the Framingham Heart Study, where magnesium intake 
was inversely associated with coronary artery calcifica-
tion.34 This could imply that magnesium acts as an inhibi-
tor of calcification, as observed in in vitro studies, where 
phosphate-induced calcification of vascular smooth 
muscle cells is prevented by magnesium, by interfering 
with secondary CPP crystal formation.35,36 Confirmatory 
ex vivo experiments in human serum demonstrated that 
the addition of 0.2 mmol/L Mg2+ increased T50 from both 
healthy controls and patients with CKD by ≈40 to 50 
minutes.36 In addition, similar improvements of calcifica-
tion propensity by magnesium was shown in randomized 
controlled intervention studies in CKD and dialysis 
patients.37,38 Multivariable regression analysis further 
indicated that age and alcohol use were independently 
associated with serum T50. This latter observation can at 
least partly be reconciled with the established risk of car-
diovascular events related to alcohol intake,39 although 
alcohol intake has not been consistently linked with vas-
cular calcification.40,41 Together, these findings suggest 
that serum T50 and the accompanying increased risks 
would be modifiable, for instance by changes in diet, 
but also by targeted therapeutic interventions aimed at, 
for example, magnesium and phosphate. It should, how-
ever, be noted that the variables remaining in the model 
(Table 2) only explain ≈28% of the variation in T50.
The association between serum T50 and the increased 
risk for cardiovascular mortality in the current population 
is in agreement with previous studies in renal transplant 
recipients18,19 but was so far not shown in the general 
population. If such an association would be confirmed 
in other general population-based cohorts, serum T50 
may prove useful as an independent cardiovascular risk 
marker in the general population. Nevertheless, serum 
T50 may have a higher predictive value in subgroups that 
are at a higher risk of developing medial calcifications 
or cardiovascular disease. In line with this, we observed 
more pronounced associations between serum T50 and 
cardiovascular mortality risk in subjects with diabetes 
mellitus, despite the small number of patients with dia-
betes mellitus in this cohort. Similarly, there was an inter-
action with BMI and plasma magnesium, showing more 
pronounced associations in subjects with a higher BMI 
and lower plasma magnesium, both characteristics that 
are also present in subjects with type 2 diabetes mel-
litus.42 Recently, in a study with type 1 diabetes melli-
tus patients serum T50 was associated with indices of 
increased mineral stress, but not with the development 
of long-term macrovascular complications, possibly due 
to the small sample size.43 Future studies may clarify the 
role of T50 as a marker of cardiovascular risk in persons 
with diabetes mellitus.
The association between serum T50 and all-cause 
mortality was weaker and lost significance after multi-
variable adjustment. All-cause mortality includes, next 
to cardiovascular-related deaths, a substantial number 
of malignancy-related deaths (n=185), showing (as 
expected) no relation to serum T50 (data not shown). In 
addition, given the associations with cardiovascular mor-
tality, we expected to find relationships between serum 
T50 and incident cardiovascular events in exploratory 
analyses, but these were not found in the present cohort. 
This may suggest that T50 is linked with more severe car-
diovascular events, leading to mortality.
It may be questioned whether the association 
between T50 and cardiovascular mortality is not mainly 
driven by phosphate concentrations. Besides stud-
ies with CKD patients, another study in the general 
Figure 1. Spline Cox proportional hazards regression models 
for the association of T50 with mortality.
Linear spline curve for cardiovascular (CV) mortality (A), and all-
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population found that fasting serum phosphate is 
associated with mortality,44 and phosphate is a strong 
determinant of T50. In an additional exploratory analy-
sis, we, therefore, assessed whether phosphate is also 
associated with cardiovascular mortality and all-cause 
mortality, but these associations were absent in our 
cohort. This emphasizes that the T50 test gives addi-
tional, clinically relevant information over the measure-
ment of phosphate concentrations.
In contrast to primary CPP, secondary CPP can 
induce calcification of vascular smooth muscle cells in 
vitro.45 Furthermore, exposure of macrophages or vas-
cular smooth muscle cells to secondary CPP induces 
a strong proinflammatory response and oxidative 
stress.45,46 This inflammatory response was found to 
further enhance the calcification process.45 Therefore, 
secondary CPP may contribute to the formation of 
calcium-phosphate precipitation and inflammation of 
soft tissue, including the arterial wall. If substantiated in 
future studies, these proposed mechanisms may caus-
ally link the result of the T50 test with cardiovascular 
mortality in the general population.
To our knowledge, this is the first study to investi-
gate the relationship between serum calcification pro-
pensity and outcomes in the general population. Other 
strengths of our study include the large sample size, 
the long duration of follow-up, the well-phenotyped 
cohort, allowing adjustment for relevant potential con-
founders, and the validated way in which causes of 
death were determined. A limitation is that serum T50 
was measured only at a single visit; therefore, we could 
not take changes in calcification propensity over time 
Figure 2. Forest plot of subanalyses for cardiovascular mortality.
Stratification was based on median values for age (< or >52.3 y), body mass index (BMI; < or >26.1 kg/m2), estimated glomerular filtration rate 
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into account. However, the availability of a single mea-
surement may lead to underestimation, rather than 
overestimation, of the true association between T50 
and outcomes. Finally, as with any observational study, 
residual confounding could, in part, explain the associa-
tion between serum T50 and the risk of cardiovascular 
mortality, despite the multivariable adjustment.
In conclusion, we found that a shorter serum T50, 
reflecting an increased calcification propensity, is 
associated with a higher risk of cardiovascular mor-
tality in a large prospective general population-based 
cohort. Serum T50 may be considered a novel indepen-
dent, and potentially modifiable, risk marker for cardio-
vascular mortality.
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